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Available online 23 June 2016Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) is a key enzyme in triacylglycerol (TG) biosynthesis. Here we
show that genetic deficiency and pharmacological inhibition of DGAT1 in mice alters cholesterol metabolism.
Cholesterol absorption, as assessed by acute cholesterol uptake,was significantly decreased in the small intestine
and liver upon DGAT1 deficiency/inhibition. Ablation of DGAT1 in the intestine (I-DGAT1−/−) alone is sufficient
to cause these effects. Consequences of I-DGAT1 deficiency phenocopy findings in whole-body DGAT1−/− and
DGAT1 inhibitor-treated mice. We show that deficiency/inhibition of DGAT1 affects cholesterol metabolism via
reduced chylomicron size and increased trans-intestinal cholesterol excretion. These effects are independent of
cholesterol uptake at the apical surface of enterocytes but mediated through altered dietary fatty acid metabo-
lism. Our findings provide insight into a novel role of DGAT1 and identify a pathway by which intestinal
DGAT1deficiency affectswhole-body cholesterol homeostasis inmice. Targeting intestinal DGAT1may represent
a novel approach for treating hypercholesterolemia.






Trans-intestinal cholesterol excretion1. Introduction
Acyl-CoA:diacylglycerol acyltransferase (DGAT)1 and 2 catalyze the
final and rate-limiting step of triacylglycerol (TG) biosynthesis mediat-
ed mainly through the 2-monoacylglycerol and glycerol-phosphate
pathways [1]. The two DGAT enzymes DGAT1 and DGAT2 are encoded
by two different genes belonging to distinct acyl-transferase families,
which lack significant sequence homology [2]. Highest expression levels
of both genes are found in tissues active in TG synthesis, such as adipose
tissue, small intestine, liver, and mammary gland [3]. In the intestine,erase; ApoE, apolipoprotein E;
intestine-specific; Inh-DGAT1,
HF/HCD, high-fat/high-choles-
; NLS, neutral sterol loss; TICE,
tky).
. This is an open access article underDGAT1 is predominantly involved in the biosynthesis of TG fromdietary
fatty acids (FA) [4]. In the postprandial state, esterified lipids generated
by intestinal DGAT1 are incorporated into chylomicron particles,
secreted into the lymphatic system, and subsequently released into
the peripheral circulation via the thoracic duct [5]. DGAT1 knockout
(DGAT1−/−) mice are viable, resistant to diet-induced obesity and
fatty liver disease, exhibit increased energy expenditure, and normal in-
sulin and leptin sensitivity [3,6]. Mice that express DGAT1 exclusively in
the small intestine are, however, susceptible to high-fat diet-induced
hepatic steatosis and obesity [7]. Loss of DGAT1 specifically in the intes-
tine leads to reduced postprandial TG and retinyl ester concentrations
due to reduced chylomicron secretion [8]. These observations implicate
intestinal DGAT1 as a potential target to reduce postprandial lipemia by
altering chylomicron biosynthesis [9].
Pharmacological DGAT1 inhibition studies in animal models have
consistently demonstrated reduction in diet-induced weight gain and
postprandial chylomicron secretion [10,11]. Pharmacological inhibitionthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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centrations in mice [12]. The utility of DGAT1 inhibitors has recently
been strengthened by studies in patients suffering from familial
chylomicronemia [13]. Thus, DGAT1 is a potential target to improve
metabolic parameters in hyperlipidemic states. Intestinal DGAT1 has
been speculated to exert these effects by increasing the secretion of
gut hormones, such as glucagon-like peptide-1 and peptide YY [14].
However, endocrine changes alone are unable to explain the observed
postprandial phenotype upon pharmacological DGAT1 inhibition and
thus the precise mechanisms regulating DGAT1 inhibitory effects still
remain elusive [8].
We have previously reported that DGAT1 deficiency in apolipopro-
tein E−/−mice has an athero-protective role. These beneficial effects in-
cluded lower plasma cholesterol concentrations and reduced intestinal
cholesterol absorption [15]. Given its predominant role in TG biosynthe-
sis, the profound reduction in cholesterol uptake and absorption is
puzzling. Our results indicate that inhibition or ablation of DGAT1 in
enterocytes is sufficient to reduce the incorporation of cholesterol esters
(CE) into chylomicrons.We speculate that the reduced chylomicron size
further facilitates the trans-intestinal excretion of cholesterol (TICE)
upon DGAT1 inhibition conferring athero-protection.
2. Materials and methods
2.1. Animals and diets
Age-matched male mice (8–12 weeks of age) were used for all
experiments unless indicated. Mice had ad libitum access to water and
food and were maintained under a 12-h light/12-h dark cycle in a
temperature-controlled environment. I-DGAT1−/− [8] and DGAT1−/−
[16] mice were generously provided by Dr. Robert Farese, Jr. (Harvard
T.H. Chan School of Public Health, Boston, MA). LDLR−/− mice
(purchased from Jackson Laboratory, Bar Harbor, ME) were crossed
with DGAT1−/− mice to generate DGAT1−/−LDLR−/− mice. All mice
were fed either regular chow diet (11.9% caloric intake from fat;
Altromin 1324, Lage, Germany) or challenged with a high-fat/high-
cholesterol diet (HF/HCD; 30% caloric intake from fat plus 1% cholesterol;
Ssniff, Soest, Germany) starting at the age of 8 weeks. The fatty acid
composition of the HF/HCD is delineated in supplementary Table S1.
Experiments to determine cholesterol fluxes upon chronic pharma-
cological DGAT1 inhibitionwere performed in compliancewith national
laws and were approved by the respective Ethical Committees for
Animal Experiments, University of Groningen, The Netherlands. For all
other studies, animal experiments were approved by the Austrian
Federal Ministry of Science, Research, and Economy, Vienna, Austria,
in accordance with the Council of Europe Conventions.
2.2. Blood biochemical analyses
Blood was collected from 4 h (6 a.m. until 10 a.m.) fasted mice and
plasma was prepared within 20 min. TG, TC, and free cholesterol (FC)
concentrations were measured enzymatically according to
manufacturer's instructions (DiaSys, Holzheim, Germany). Lipoprotein
fractions were separated from 200 μl pooled plasma from each group
using fast protein liquid chromatography (Pharmacia P-500) equipped
with a Superose 6 column (Amersham Biosciences, Piscataway, NJ). TC
concentrations in the isolated fractions were measured enzymatically.
2.3. Acute pharmacological DGAT1 inhibition
The DGAT1 inhibitor used in this study has been described
elsewhere as compound 2 [11]. Dosage for the inhibitor treatment
was chosen based on a previous report [8]. Treatments were initiated
one day before start of the experiment at 8 a.m. after a 2 h fasting period
andwere repeated every 24 h during the course of the experiment.Mice
had access to food 2 h post treatment. Wild-type mice on a C57BL/6background were orally dosed with either vehicle composed of 0.5%
(w/v) of hydroxypropylmethylcellulose (Sigma-Aldrich, St. Louis, MO)
in 0.1% (v/v) Tween 80 or DGAT1 inhibitor (5 mg/kg body weight)
dissolved in vehicle. On the day of cholesterol absorption experiments
(described below) mice were gavaged with corn oil containing radio-
tracers 2 h post DGAT1 inhibitor treatment.
2.4. Short-term cholesterol absorption
Cholesterol absorption studies were performed as described previ-
ously [15]. Briefly, chow diet-fed mice were fasted for 4 h and gavaged
with 200 μl corn oil containing 2 μCi [3H]cholesterol (ARC Inc., St
Louis, MO) and 200 μg cholesterol. After 4 h, plasma, liver, and three
parts of the small intestine were isolated. Duodenum, jejunum, and
ileum were rinsed with PBS to remove luminal contents. The tissues
were dissolved in 1 M NaOH at 65 °C overnight for protein quantitation
and analyzed by liquid scintillation counting.
2.5. Fractional cholesterol absorption
Fractional cholesterol absorption was measured by the fecal dual-
isotope ratio method as described [15]. Chow diet-fed mice were fasted
for 4 h and gavaged with a single dose of 200 μl corn oil containing
0.2 μCi [3H]sitostanol (ARC Inc., St. Louis,MO) and 0.1 μCi [14C]cholesterol
(ARC Inc., St. Louis,MO). Feceswere collected for 72 h and lipidswere ex-
tracted using the Folch extractionmethod. Radioactivity in fecal samples
was measured by liquid scintillation counting. Fractional cholesterol ab-
sorption was calculated using the following formula: % absorption =
(dose [14C]:[3H] − fecal [14C]:[3H])/ dose [14C]:[3H] × 100.
2.6. Uptake and secretion of cholesterol by primary enterocytes
Primary enterocytes were isolated from overnight fasted C57BL/6
mice, suspended in 4 ml of DMEM, and incubated at 37 °C as described
[17]. DMEM was supplemented with either vehicle (DMSO) or DGAT1
inhibitor (EC50 = 0.03 μm, dissolved in DMSO) and 1 μCi/ml [-
3H]cholesterol suspended in mixed lipid micelles (0.14 mM sodium
cholate, 0.15 mM sodium deoxycholate, 0.17 mM phosphatidylcholine,
0.19 mMmono-oleoylglycerol). Cholesterol uptake was determined at
indicated time points, after which enterocytes were washed, cellular
lipids were extracted, and radioactivity was measured by liquid scintil-
lation counting. For determination of cholesterol secretion, enterocytes
were labeled for 1 h and chased with medium containing secretion
micelles (1.4 mM oleic acid, 0.14 mM sodium cholate, 0.15 mM sodium
deoxycholate, 0.17 mM phosphatidylcholine, 0.19 mM mono-
oleoylglycerol) in the absence and presence of DGAT1 inhibitor. After
2 h of chase, enterocytes were centrifuged, lipids were extracted from
the supernatant and separated by thin layer chromatography to quanti-
fy enterocyte [3H]cholesterol secretion into FC and cholesteryl ester
(CE) fractions [17].
2.7. Chylomicron secretion
Chylomicron secretion rate using [9, 10-3H(N)]triolein (Perkin
Elmer, Boston, MA) and [14C]cholesterol (ARC Inc., St. Louis, MO) was
assessed as previously described [8] with minor modifications. Briefly,
mice fed HF/HCD for 12 weeks were fasted for 4 h starting at 6 a.m.
Thereafter, they were intraperitoneally injected with Poloxamer-407
(P-407; 1 g/kg body weight, Sigma-Aldrich, St. Louis, MO) in PBS and
gavaged with 200 μl corn oil containing 1 μCi [3H]triolein, 0.5 μCi [-
14C]cholesterol, and 200 μg cholesterol. Prior to P-407 injection and
post 1, 2, 3, and 4 h corn oil gavage, blood samples were collected and
radioactivity was measured in the plasma. Four hours post gavage,
mice were anaesthetized and lymph was surgically removed as de-
scribed [18] with modifications. Briefly, anaesthetized mice were asep-
tically prepared for surgery and the abdomenwas opened through a left
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mobilize spleen, liver, and stomach to expose the cisterna chyli and
the thoracic duct-containingpostprandialmilky lymph. Under a dissect-
ing microscope, lymph was carefully collected using glass micro-
capillary tubes. Radioactivity in a pool of 100 μl lymph was measured
by liquid scintillation counting.
2.8. Chylomicron size measurement
Mice fed HF/HCD for 12 weeks were fasted for 4 h starting at 6 a.m.,
intraperitoneally injected with P-407, and gavaged with 200 μl corn
oil. Ninety minutes post gavage, blood and lymph were isolated as
described above. Plasma chylomicrons were separated by density-
gradient centrifugation as described [19]. Briefly, 0.4 ml of plasma was
mixed with 0.9 ml PBS (containing 2 mM benzamidine) and 0.7 g KBr
(4 M final concentration, density 1.3 g/ml). The mixture was placed
into 5.5 ml Quick-Seal centrifugation tubes (Beckman Coulter, Brea,
CA), carefully overlayed with 0.9% NaCl, and centrifuged for 45 min at
416,000g (65,000 rev/min; VTi 65.2 rotor). Fractions were collected
from the bottom of the tubes and the densities were determined. The
top fraction contained chylomicrons. We processed the chylomicron-
containing fraction for particle size analysis [19] by dynamic light scat-
tering using a Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern,
UK) at 25 °C according tomanufacturer's instructions. Particle sizemea-
surements were performed in triplicate and averaged. Data represent
averages from 4 independent experiments and are indicated as mean
hydrodynamic diameter in nanometer scale (Z-Average dnm).
2.9. Hematoxylin and eosin staining
Jejuna of overnight fasted HF/HCD-fed DGAT1fl/fl and I-DGAT1−/−
mice were fixed in 4% neutral-buffered formaldehyde for 24 h and em-
bedded in paraffin. Sections (5 μm) were deparaffinized and subjected
to hematoxylin and eosin staining.
2.10. Freeze-fracture transmission electron microscopy
Five microliters of postprandial lymph and plasma chylomicrons
from HF/HCD-fed mice were subjected to freeze-fracture transmission
electron microscopy as described previously [20]. Images were
taken using a FEI Tecnai G2 20 transmission electron microscope (FEI,
Eindhoven, The Netherlands) with a Gatan ultrascan 1000 CCD camera.
Acceleration voltage was 120 kV. Particle size distribution of 100–200
particles from 18 electron micrographs was estimated using Image J
software (ImageJ 1.43U, NIH, USA).
2.11. Quantification of fecal neutral sterol loss, bile acid and fatty acid
concentrations
Feces were collected for 72 h from individually housed mice. Fifty
micrograms of dried feces were used for determination of fecal neutral
sterol loss (NSL), bile acid (BA) concentrations, and FA composition by
gas chromatography as described recently [21,22].
2.12. Measurement of TICE
C57BL/6micewere purchased fromHarlan (Horst, TheNetherlands)
and fed high-fat diet (HFD; 60% caloric intake from fat; Research Diet
Services, Wijk Bij Duurstede, The Netherlands) supplemented with ei-
ther vehicle or DGAT1 inhibitor (5 mg/kg diet) for 4 weeks. The fatty
acid composition of the HFD is delineated in Table S1. Cholesterol flux
experiments tomeasure TICEwere performed as described [23]. Briefly,
mice were orally gavaged at day 0 with 1.5 μmol cholesterol-D5
(Medical Isotopes, Inc., Pelham, NH, USA) dissolved inMCT oil (Pharmacy
UMCG, Groningen, The Netherlands) and were intravenously injected
with 0.7 μmol cholesterol-D7 (Cambridge Isotope Laboratories, Inc.,Andover, MA, USA) dissolved in Intralipid (20%, Fresenius Kabi, Den
Bosch, The Netherlands). Blood spots were collected from the tail daily
for 10 days. On day 10,micewere anaesthetized and hepatic bilewas sur-
gically collected for 20min from the commonbile duct via the gallbladder
as described previously [23]. Tissues were excised and feces were collect-
ed from individual mice for 72 h prior to termination. Fecal NSL, BA, and
FA concentrations were measured as described above.
2.13. Statistics
Statistical analyses were performed using GraphPad Prism 5.0 soft-
ware (San Diego, CA). Data are presented asmean± SEM. Comparisons
between 2 groups were measured using unpaired 2-tailed Student's
t-test. Comparisons of multiple groups were analyzed by 2-way
ANOVA followed by Bonferroni post-tests. Significance levels were set
at p b 0.05 (*), p ≤ 0.01 (**), and p ≤ 0.001 (***).
3. Results
3.1. Intestinal DGAT1 deficiency reduces cholesterol absorption to levels
that are comparable to global DGAT1 deficiency and pharmacological
DGAT1 inhibition
To analyze cholesterol metabolism, we first investigated short-term
and fractional cholesterol absorption between I-DGAT1−/−, DGAT1−/−,
and DGAT1-Inh mice and their respective controls. Absence or inhibi-
tion of DGAT1 resulted in significantly decreased acute cholesterol ab-
sorption as indicated by reduced radioactivity in all parts of the small
intestine by N50% and in liver (50%, 82%, and 92%, respectively) of I-
DGAT1−/−, DGAT1−/−, and DGAT1 inhibitor-treated (DGAT1-Inh)
mice (Fig. 1A, B).
The radiotracer was retained considerably in the stomachs of I-
DGAT1−/−, DGAT1−/−, and DGAT1-Inh mice compared to their respec-
tive controls (1.7-fold, 2.6-fold, and 2.6-fold, respectively) (Fig. 1C). In
addition, we observed reduced radioactivity in the plasma of I-
DGAT1−/− and DGAT1-Inh mice (73% and 90%, respectively) (Fig. 1D).
We then measured fractional cholesterol absorption in these mice by
using the fecal dual-isotope method, in which feces were collected for
72 h after a single intragastric bolus of radiolabeled cholesterol and
sitosterol. As shown in Fig. 1E, fractional cholesterol absorption was
reduced in I-DGAT1−/−, DGAT1−/−, and DGAT1-Inh mice by 27%, 43%,
and 32%, respectively, compared to their respective controls.
3.2. Intestinal DGAT1 deficiency reduces plasma cholesterol levels in HF/
HCD-fed mice
Previous reports have described reduced body-weight gain and im-
proved metabolic profile upon DGAT1 deficiency when mice were fed
with increased dietary fat [3,4]. We hypothesized that challenging glob-
al and intestinal DGAT1-deficientmicewith increased fat and cholester-
ol will mimic these observations. Thus, we investigated the impact of
intestinal DGAT1 deficiency on cholesterol metabolism in HF/HCD-fed
mice over a period of 20 weeks. Body-weight gain was reduced in
I-DGAT1−/− mice compared to controls starting 4 weeks after initiation
of the diet and sustained until the end of the feeding period (Fig. 2A).
Moreover, upon 4 h of fasting, I-DGAT1−/− mice exhibited comparable
plasma TG but reduced TC and CE concentrations (35% and 39%, respec-
tively) compared to DGAT1fl/fl mice (Fig. 2B). Plasma lipoprotein pro-
files after separation by fast protein liquid chromatography revealed
decreased LDL and HDL cholesterol levels in I-DGAT1−/− mice
(Fig. 2C). To investigate whether intestinal DGAT1 deficiency had any
impact on small intestinal morphology we stained intestinal sections
with hematoxylin and eosin. As shown in Fig. 2D, we observed intact
villi morphology in I-DGAT1−/− mice with reduced lipid accumulation.
We observed comparable results in whole-body DGAT1−/− mice and
Fig. 1. Intestinal DGAT1 deficiency reduces cholesterol absorption comparable to global DGAT1 deficiency and pharmacological DGAT1 inhibition. (A–D) Mice (n = 4–7) were gavaged
with 200 μl corn oil containing 2 μCi [3H]cholesterol and 200 μg cholesterol. Radioactivity was measured 4 h post-gavage in (A) duodenum, jejunum, ileum, (B) liver, (C) stomach, and
(D) plasma by liquid scintillation counting. (E) Fractional cholesterol absorption was determined using the fecal dual-isotope method (n = 5–10). Values represent mean + SEM.
Student's t-test was used to compare grouped controls. *p b 0.05, **p b 0.01, ***p b 0.001.
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Fig. 2A, B).
3.3. DGAT1 inhibition reduces CE secretion from enterocytes
We next investigated whether cholesterol retention in the stomach
is the primary cause of reduced cholesterol absorption or whether
DGAT1 deficiency in enterocytes alters cholesterol metabolism inde-
pendent of gastric emptying. Thus, we performed ex vivo enterocyte
cholesterol uptake and secretion studies upon DGAT1 inhibition in
enterocytes isolated from wild-type mice. We observed unaltered cho-
lesterol uptake in DGAT1-Inh enterocytes compared to vehicle-treated
enterocytes (Fig. 3A). Secretion of both FC and CE was reduced in
DGAT1-Inh enterocytes by 27% and 32%, respectively, compared to
vehicle-treated enterocytes (Fig. 3B, C). These results indicate that
DGAT1 activity in enterocytes directly regulates cholesterol uptake
and absorption.
3.4. Intestinal DGAT1 deficiency alters chylomicron size and lymph lipid
content
Newly synthesized post-prandial chylomicrons from the intestine
are first transported to the lymph before being released into systemic
circulation [5]. Thus, we administered mice with radiolabeled triolein
and cholesterol, chased post-prandial plasma, and collected lymph 4 hpost-administration of the radiotracers. Radioactive counts from
lymph and plasma may provide a rough estimate of administered TG
and CE incorporated into the newly synthesized chylomicrons. In fact,
secretion of [3H]triolein- (Fig. 4A) and [14C]cholesterol-derived counts
(Fig. 4B) were drastically reduced in plasma of I-DGAT1−/− compared
to DGAT1fl/fl mice. In addition, [3H]triolein- and [14C]cholesterol-
derived counts in the lymph were decreased by 85% and 92%, respec-
tively (Fig. 4C, D). We then isolated plasma chylomicrons and lymph
from P-407-treated mice after 90 min of fat challenge and subjected
them to dynamic light scattering (DLS) and electronmicroscopy to esti-
mate their size. Plasma chylomicrons of I-DGAT1−/− mice were signifi-
cantly (20%) smaller as measured by DLS (Fig. 4E). The polydispersity
index for all measured samples was between 0.1 and 0.2 indicating nar-
row size distribution of particles. Visualization of chylomicrons in
lymph (Fig. 4F, top panel) and plasma (Fig. 4F, bottom panel) by elec-
tron microscopy and their quantification confirmed smaller particle
size in I-DGAT1−/− compared to DGAT1fl/fl mice (Fig. 4G, H). We
observed similar reductions in chylomicron size in DGAT1−/− mice
(Supplementary Fig. S3).
3.5. Intestinal DGAT1 deficiency leads to increased fecal NSL and FA
excretion in HF/HCD-fed mice
Since reduced cholesterol absorption in mice has been shown to in-
crease fecal NSL [23], we measured fecal NSL and FA excretion in feces
Fig. 2. IntestinalDGAT1deficiency reduces plasma cholesterol concentrations. DGAT1fl/fl and I-DGAT1−/−micewere fedHF/HCD for 20weeks. (A) Bodyweights (n=17–19untilweek 12,
n = 5–6 until week 20). (B) Plasma TG, TC, and FC concentrations were measured spectrophotometrically. CE concentrations were determined as subtraction of FC from TC (n = 5–6).
(C) Lipoprotein profile of TC after separation by fast performance liquid chromatography of pooled plasma (n = 5–6). (D) Hematoxylin and eosin staining of duodenal sections. Top
panel: magnification, 10×; scale bar, 200 μm. Bottom panel: magnification, 40×; scale bar, 50 μm. Values represent mean ± SEM. A: 2-way ANOVA followed by Bonferroni post-test;
B: Student's t-test. *p b 0.05, **p b 0.01, ***p b 0.001.
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12 weeks. Total fecal NSL was 1.4-fold higher in I-DGAT1−/− mice
(Fig. 5A). In accordance, fecal cholesterol was significantly increased inFig. 3. DGAT1 inhibition reduces enterocyte cholesteryl ester secretion. Enterocytes were isolat
0.03 μM), and radiolabeled with 1 μCi [3H]cholesterol/ml. (A) Enterocyte [3H]cholesterol upta
uptake, enterocytes were washed and chased with media containing 1.4 mM oleic acid micell
and (C) CE fractions. A: 2-way ANOVA followed by Bonferroni post-test; B, C: Student's t-test.I-DGAT1−/− mice (Fig. 5B). Fecal total BA (Fig. 5C) and cholic acid
(CA)-derived BA (Fig. 5D) concentrations were comparable in both
genotypes. Fecal chenodeoxycholic acid (CDCA)-derived BA levelsed from overnight fasted C57BL/6 mice, treated with either vehicle or DGAT1-Inh (EC50 =
ke was measured at indicated time points (n = 3). (B, C) One hour after [3H]cholesterol
es for 2 h. Lipids were isolated, subjected to TLC, and radioactivity was counted in (B) FC
**p b 0.01.
Fig. 4. Intestinal DGAT1 deficiency alters chylomicron size and lymph lipid composition. (A–D) DGAT1fl/fl and I-DGAT1−/− mice (n = 4) fed HF/HCD were fasted for 4 h, injected
intraperitoneally with poloxamer-407 (1 g/kg body weight, in PBS), and gavaged with 200 μl corn oil containing 1 μCi [3H]triolein, 0.5 μCi [14C]cholesterol, and 200 μg cholesterol.
(A, C) [3H]triolein-derived counts in (A) plasma and (C) lymph and (B, D) [14C]cholesterol-derived counts in (B) plasma and (D) lymph were determined by liquid scintillation counting.
(E–H) Plasma and lymph was collected 90 min post-gavage of 200 μl corn oil. (E) Postprandial plasma chylomicron size was measured by Zetasizer nano. (F) Electron micrographs of
isolated lymph (top panel) and plasma chylomicrons (bottom panel). Distribution of particles size of (G) lymph and (H) plasma chylomicrons from 18 electron micrographs was
analyzed by image J software. Values represent mean ± SEM. A, B: 2-way ANOVA followed by Bonferroni post-test; C–E: Student's t-test. *p b 0.05, **p b 0.01, ***p b 0.001.
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no changes in hepatic Cyp7a1 mRNA expression in I-DGAT1−/− com-
pared to DGAT1fl/fl mice (supplementary Fig. S4). Fecal excretion of sat-
urated FA (SFA), mono-unsaturated FA (MUFA), and poly-unsaturated
FA (PUFA) was markedly increased in I-DGAT1−/− mice (Fig. 5F–H).mRNA and protein expression levels of several candidate genes, howev-
er, were unaltered in duodena of I-DGAT1−/− mice (Supplementary
Fig. S5). These results suggest that intestinal DGAT1 deficiency reduces
the incorporation of dietary FA into neutral lipids and results in
increased fecal FA and cholesterol excretion.
Fig. 5. Intestinal DGAT1 deficiency leads to increased fecal neutral sterol and fatty acid excretion in HF/HCD-fed mice. Feces of HF/HCD-fed mice (n = 10–12) were collected for 72 h.
Neutral sterols, bile acids (BA), and fatty acids (FA) were measured by gas chromatography. (A) Total fecal neutral sterols, (B) cholesterol, (C) total BA, (D) cholic acid (CA)-derived
BA, and (E) chenodeoxycholic acid (CDCA)-derived BA, (F) saturated FA (SFA), (G) mono-unsaturated FA (MUFA), and (H) poly-unsaturated FA (PUFA) are indicated. Values represent
mean + SEM. *p b 0.05, **p b 0.01, ***p b 0.001, Student's t-test.
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via enhanced TICE
To determine whether chronic pharmacological DGAT1 inhibition
phenocopies changes in cholesterol metabolism observed in
I-DGAT1−/− mice we measured fecal NSL and cholesterol flux in
DGAT1-Inh mice. Comparable with the results from I-DGAT1−/− mice,
DGAT1-Inh mice exhibited increased fecal NSL (Fig. 6A) accompanied
by elevated secretion of fecal cholesterol (Fig. 6B). Increased fecal NSL
was independent of BA excretion as fecal total BA, CA-derived BA, and
CDCA-derived BA concentrations were comparable between DGAT1-
Inh and vehicle-treated mice (Fig. 6C-E). Moreover, biliary cholesterol
secretion remained constant between the two groups (Fig. 6F) indicat-
ing the possibility of altered TICE, which indeed was increased by 1.4-
fold in DGAT1-Inh mice (Fig. 6G). Although fecal excretion of PUFAwas unaffected (Fig. 6H), fecal SFA and MUFA concentrations were
significantly increased in DGAT1-Inh compared to vehicle-treated
mice (Fig. 6I, J).
4. Discussion
In the present study, we show that intestinal DGAT1 deficiency
is sufficient to alter whole-body cholesterol homeostasis in mice.
DGAT1−/− mice are resistant to diet-induced weight gain but the
phenotype is reversed when DGAT1 is expressed only in the intestine
[3,7]. It is well accepted that intestinal DGAT1 deficiency drives the
reduction in high fat diet-induced weight gain in DGAT1−/− mice. Our
study provides evidence that intestinal DGAT1 deficiency alone is
sufficient to prevent diet-induced weight gain and lowers cholesterol
levels in HF/HCD-fed mice.
Fig. 6. Pharmacological DGAT1 inhibition in HFD-fed mice increases fecal neutral sterol loss via enhanced trans-intestinal cholesterol excretion (TICE). Mice (n = 8) were fed HFD
supplemented with either vehicle or DGAT1-Inh (5 mg/kg diet) for 4 weeks. Feces were collected for 72 h and neutral sterols, bile acids (BA), and fatty acids (FA) were measured by
gas chromatography. (A) Total fecal neutral sterols, (B) cholesterol, (C) total bile acids (BA), (D) cholic acid (CA)-derived BA, (E) chenodeoxycholic acid (CDCA)-derived BA, (F) biliary
cholesterol secretion, (G) TICE, (H) poly-unsaturated FA (PUFA), (I) saturated FA (SFA), and (J) mono-unsaturated FA (MUFA) are indicated. Values represent mean + SEM. *p b 0.05,
Student's t-test.
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in humans have been consistent with animal studies but their develop-
ment as a therapeutic target for obesity, diabetes, and hyperlipidemia
have been hampered due to unwanted gastro-intestinal side effects[24,25]. Pharmacological inhibitors of enzymes involved in chylomicron
metabolism (such as ACAT2 and microsomal triglyceride transfer
protein) in human trials have met with a similar fate [26,27]. Of note,
we observed no diarrheal phenotype in I-DGAT1−/−, DGAT1−/− or
1140 V. Sachdev et al. / Biochimica et Biophysica Acta 1861 (2016) 1132–1141DGAT1-Inh mice since mice may be less dependent on DGAT1 function
[16] than humans. Increased plasma GLP-1 levels due to DGAT1 inhibi-
tion in humans and animals models leads to delayed gastric emptying,
which might lead to vomiting and diarrhea in humans [8,24]. Thus,
understanding and exploring the chylomicron neutral lipid balance
could help in generating better tolerable inhibitors targeting the gut
metabolism to treat hyperlipidemia and obesity.
We have shown that loss of DGAT1 on the ApoE-deficient back-
ground results in lower plasma cholesterol concentrations and reduced
intestinal cholesterol absorption [15]. However, whether cholesterol
concentrations and cholesterol metabolism per se are altered upon
intestinal or systemic DGAT1 deficiency have not been explored. In
the current study, we found that secretion of post-prandial [3H]triolein-
and [14C]cholesterol-derived counts in chylomicrons were markedly
reduced in I-DGAT1−/− mice. Ables et al. have previously reported re-
duced chylomicron secretion with reduced postprandial TG and retinyl
ester excursions in I-DGAT1−/− mice [8]. DGAT1 possesses acyl-
CoA:retinol acyltransferase activity [28], which could partly explain
the reduction in chylomicron retinyl ester excursion due to intestinal
DGAT1 deficiency. However, no acyl-CoA:cholesterol transferase activi-
ty has been reported for DGAT1. Our results suggest that enterocyte
DGAT1 deficiency disturbs the intricate balance of dietary lipid esterifi-
cation for chylomicron assembly, resulting in reduced TG, retinyl ester,
and CE concentrations in chylomicrons.
We found increased fecal FA excretion in HF/HCD-fed I-DGAT1−/−
and HFD-fed DGAT1-Inh mice. In agreement with our observations,
Denison et al. reported on increased FA concentrations in stools of
human subjects treated with the same DGAT1-Inh used in our study
[24]. These results suggest that DGAT1 inhibition leads to increased
fecal FA excretion since TG re-esterification by DGAT1 and incorpora-
tion into chylomicrons is pivotal for channeling dietary FA for chylomi-
cron assembly. Consistently, we observed significantly reduced body
weight gain in DGAT1-Inh mice fed HFD for 4 weeks (data not
shown). Thus, increased fecal FA excretion upon high-fat diet feeding
might contribute to the lack of body weight gain observed in our
mouse models. In contrast to our results, a previous study by Cases
et al. reported on unchanged fecal fat in HFD-fed Dgat1−/− mice [16].
The discrepancy between the two studies could partly be explained by
differences in diet composition.
Reduced postprandial [3H]triolein- and [14C]cholesterol-derived
counts assuming decreased TG and CE chylomicron concentrations in
I-DGAT1−/− mice resulted in smaller chylomicron size, similar to
what we have observed in DGAT1−/− mice. Studies in rats have
shown that smaller chylomicron-sized particles are cleared faster from
the circulation than large chylomicrons, possibly due to an increased
surface area available for lipoprotein lipase to cleave TGwithin lipopro-
teins [29]. Smaller chylomicron particles and, thus, more efficient plas-
ma clearance could account for reduced body weight gain and an
improved metabolic profile in HF/HCD-fed I-DGAT1−/− mice. Of note,
reduction in postprandial chylomicron size is specific for intestinal
DGAT1 deficiency because in the absence of intestinal acyl-CoA choles-
terol transferase 2 (ACAT2), chylomicrons were depleted in CE, which
were shown to be replaced mainly by TG without particle size alter-
ations and unchanged fecal fat excretion [19]. We speculate that
DGAT1 does not directly affect CE biosynthesis, but that the alterations
in TG metabolism contribute to the altered cholesterol absorption
observed in I-DGAT1−/− and DGAT1−/− mice.
Acute and fractional cholesterol absorption were considerably re-
duced in chow diet-fed I-DGAT1−/−, DGAT1−/−, and DGAT1-Inh mice.
These results indicate that intestinal DGAT1 deficiency alone is suffi-
cient to reduce cholesterol absorption to levels comparable to global
DGAT1 deficiency or DGAT1 inhibition. Delayed gastric emptying is a
well-known phenomenon in I-DGAT1−/− and DGAT1−/− mice as well
as upon inhibition in mouse models and humans [8,14,24,30]. Treat-
ment of I-DGAT1−/− mice with the glucagon-like peptide-1 antagonist
Exendin-9 corrected for delayed gastric emptying but the reducedpostprandial TG and retinyl ester excursion was shown to persist [8].
In addition, a previous report suggests an inverse correlation between
the rate of gastric emptying and cholesterol absorption [31]. Thus,
delayed gastric emptying might not be the sole factor responsible for
reduced cholesterol absorption in I-DGAT1−/− mice. To exclude the
possibility that endocrine changes trigger reduced cholesterol absorp-
tion, we performed ex vivo enterocyte studies upon pharmacological
DGAT1 inhibition. Reduced CE secretion but unaltered cholesterol up-
take in DGAT1-Inh enterocytes suggests that DGAT1 inhibition reduces
cholesterol absorption by decreasing CE secretion into chylomicrons.
We speculate that the DGAT1 deficiency/inhibition-induced delay in
gastric emptying could only be a contributing factor but not a decisive
mechanism altering chylomicron secretion in murine models and
human studies.
Decreased cholesterol absorption in I-DGAT1−/− mice was reflected
by reduced circulating plasma TC and CE concentrations in I-DGAT1−/−
mice, particularly in HDL and LDL fractions. This finding is in line with
data of human volunteers where a significant reduction in plasma TC
and LDL-C concentrations has been observed upon pharmacological
DGAT1 inhibition (Turnbull AV, personal communication). In addition,
we observed reduced bodyweight gain and circulating TC andCE concen-
trations in DGAT1−/−LDLR−/− compared to LDLR−/− mice fed HF/HCD
for 8 weeks. Together with our previous data on DGAT1−/−ApoE−/−
mice [15], we conclude that DGAT1 deficiency/inhibition-mediated re-
duction in cholesterol concentration is independent of the ApoE-LDLR-
mediated clearance of chylomicron remnants but is a direct result of
reduced dietary cholesterol incorporation into chylomicrons.
We had speculated that altered NPC1L1 levels [32] could result in
the observed decreased systemic cholesterol concentrations and
increased fecal NSL in I-DGAT1−/− mice. However, unchanged uptake
of [3H]cholesterol in our ex vivo studies and unaltered intestinal
NPC1L1 protein concentrations in I-DGAT1−/− mice does not support
this possibility. Our finding of unchanged hepatic Cyp7A1 mRNA ex-
pression in I-DGAT1−/− mice together with unaltered biliary cholester-
ol secretion observed upon DGAT1 inhibition limits the possible
involvement of hepato-biliary excretion pathways in regulating choles-
terol metabolism in DGAT1 deficiency or inhibition. Reduced cholester-
ol absorption is known to increase the excretion of unabsorbed
cholesterol in the feces [23]. TICE, the non-biliary route of direct secre-
tion of cholesterol by the intestine, has been shown to account for
~30% of total fecal NSL excreted by wild-type mice [23]. Indeed, TICE
was augmented by 1.4-fold in DGAT1-Inh mice. From these findings
we conclude that changes in cholesterol metabolism in DGAT1-
deficient and-inhibited mice are mainly a consequence of alterations
in TICE.
In accordance with our results, a recent report has suggested that
apolipoprotein B–containing lipoproteins might be the preferred
cholesterol substrate for TICE. The basolateral lipoprotein receptors as
well as intracellular trafficking pathways involved in TICE, however,
have remained elusive [33]. Factors that regulate TICE include liver X
receptor activation and peroxisome proliferator-activated receptor δ
ligands [23,34]. We exclude these factors as being critically involved in
explaining the I-DGAT1−/− phenotype sincemRNA and protein expres-
sion levels of several candidate genes were unaltered in duodena of
I-DGAT1−/− mice (Supplementary Fig. S5). We consider the smaller-
sized chylomicrons in I-DGAT1−/− mice being the source of increased
fecal FA concentrations and NSL. To our knowledge, no study has so
far linked smaller chylomicron particles inmice to changes in their exo-
cytosis or in TICE. Future studies directed towards exploring chylomi-
crons as a substrate for TICE should shed more light to our hypothesis.
5. Conclusion
We conclude that deficiency and inhibition of DGAT1 affect
cholesterol metabolism in mice due to reduced cholesterol absorption,
smaller chylomicron size, and increased TICE. These effects are likely
1141V. Sachdev et al. / Biochimica et Biophysica Acta 1861 (2016) 1132–1141independent of cholesterol uptake by the intestine but mediated
through altered dietary FA metabolism in the intestine. Our study
shows that there exists an intricate balance between incorporation of
TG and other neutral lipids into chylomicrons. Thus, a DGAT1-
dependent decrease in chylomicron TG likely results in reduced
incorporation of CE and RE into the chylomicron, which ultimately
leads to smaller-sized chylomicron cargo. Understanding and exploring
this chylomicron neutral lipid balance could help in generating better
tolerable inhibitors targeting the gutmetabolism to treat hyperlipidemia
and obesity.
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